Clinical Edge Journal Scan

Patients with multiple sclerosis at an increased risk for cardiovascular diseases


 

Key clinical point: Genetic liability to multiple sclerosis (MS) was associated with an increased risk for coronary artery disease (CAD), myocardial infarction (MI), heart failure (HF), all-cause stroke (AS), and any ischemic stroke (AIS), but not atrial fibrillation (AF) or other stroke subtypes.

Major finding: Genetic liability to MS was associated with an increased risk for CAD (odds ratio [OR] 1.02; P = .03), MI (OR 1.03; P = .01), HF (OR 1.02; P = .02), AS (OR 1.02; P = .02), and AIS (OR 1.02; P = .04), but not with AF or other stroke subtypes.

Study details: This was a two-sample Mendelian randomization analysis of genetic summary data for 47,429 MS (68,374 healthy controls [HC]), 60,801 CAD (123,504 HC), and 43,676 MI (128,199 HC), 60,620 AF (970,216 HC), and 47,309 HF (930,014 HC) cases from large-scale genome-wide association studies.

Disclosures: The study was supported by grants from Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang, China, the Major Project of Science and Technology Innovation 2025 in Ningbo, and others . The authors declared no conflicts of interest.

Source: Yang F et al. Multiple sclerosis and the risk of cardiovascular diseases: A Mendelian randomization study. Front Immunol. 2022;13:861885 (Mar 15). Doi: 10.3389/fimmu.2022.861885

Recommended Reading

Neighborhood-level data sheds new light on racial and ethnic diversity in MS
ICYMI Multiple Sclerosis
The Enigma of MS Etiology: Find an Answer, Ask More Questions
ICYMI Multiple Sclerosis
Childhood abuse may increase risk of MS in women
ICYMI Multiple Sclerosis
MS: Fingolimod cessation safe if followed by prompt commencement of new therapy
ICYMI Multiple Sclerosis
PMS: pNfL could serve as biomarker for disability progression and drug response
ICYMI Multiple Sclerosis
Adverse childhood experiences associated with increased multiple sclerosis risk in women
ICYMI Multiple Sclerosis
Relapsing MS: Ofatumumab demonstrates superior benefit-risk profile than teriflunomide in RDTN patients
ICYMI Multiple Sclerosis
Multiple sclerosis: B-cell depleting therapies hinder nAb response following SARS-CoV-2 vaccination
ICYMI Multiple Sclerosis
Progression independent of relapse activity is a major cause of CDA in early relapsing MS
ICYMI Multiple Sclerosis
Maternal and infant outcomes in pregnant patients with MS treated with natalizumab
ICYMI Multiple Sclerosis